OTLKOutlook Therapeutics, Inc.
The Read
Historically, OTLK's stock has surged dramatically around its June 30 split-related events, with median absolute moves of about 371%.
The schedule
- Thu15Oct
Time window in which Outlook Therapeutics is likely to pursue an equity or debt financing, ATM usage, or similar capital raise to support ongoing ONS-5010 activities given its small cash balance and negative equity position.
- Tue15Dec
Possible announcement of a regional or global partnership or licensing deal for ONS-5010 that could provide non-dilutive funding and commercial infrastructure in ophthalmology.
- Thu11Feb
- Sun28Feb
Full-year 2026 results and 2027 outlook, including updated auditor assessment of going-concern status, cash runway, and strategic options for ONS-5010.
- Fri14May
Past
- Thu13Aug
Q2 2026 earnings call where Outlook Therapeutics is expected to update operating cash burn, debt covenants, and runway for ONS-5010 development and commercialization plans.
- Wed12Aug
An update on the regulatory path for ONS-5010 (Lytenava) in wet AMD, including FDA feedback on resubmission plans or additional data needs, should serve as a major binary catalyst for Outlook Therapeutics at approximately $0.29.
- Tue30Jun
Actual outcome: Bull · $0.98 at outcome
Outlook Therapeutics announced that it successfully regained compliance with Nasdaq's minimum bid price requirement without needing to execute a previously authorized reverse stock split. The stock rallied because avoiding a reverse split removes a significant negative overhang, sparing shareholders from the typical downward price pressure and dilution fears associated with such corporate actions.
With Outlook Therapeutics trading near $0.29, the company faces ongoing Nasdaq minimum bid-price compliance risk and may move toward a reverse split or other remediation plan by mid-2026.
- Fri15May
Actual outcome: Bull · $1.16 at outcome
Outlook Therapeutics reported a fiscal Q2 loss that missed some consensus estimates, alongside an in-line reported EPS of -$0.38. Despite the earnings deficit, the stock surged over 400% to easily exceed the $0.40 bull target, driven by the accompanying corporate update on their bevacizumab treatment for retina diseases which likely provided highly favorable news regarding clinical progress or cash runway.
Q1 2026 results and the accompanying 10-Q should update burn, debt metrics, and cash runway, signalling how urgent a financing or partnering transaction has become for Outlook Therapeutics at around $0.29 per share.
